Table 2.
Experiences and attitudes among HIV medical care providers in China (n=777).
| Variable | Total, n (%) | |||
| Number of persons living with HIV in treatment in the past month |
|
|||
|
|
≤50 | 461 (59.3) | ||
|
|
>50 | 316 (40.7) | ||
| Ever prescribed nPEPa | 414 (53.3) | |||
| Ever prescribed oPEPb | 197 (25.4) | |||
| Self-reported having a written oPEP guideline in place | 575 (74.0) | |||
| Key populations seeking nPEP help over the past 6 months |
|
|||
|
|
Often/occasionally (more than 1 per month) | 312 (40.2) | ||
|
|
Never/rarely (less than 1 per month) | 465 (59.8) | ||
| Having barriers for prescribing nPEP in place | 236 (30.4) | |||
| nPEP-related attitudes |
|
|||
|
|
Have adequate time to prescribe nPEP |
|
||
|
|
|
Agree | 458 (58.9) | |
|
|
|
Neutral | 235 (30.2) | |
|
|
|
Disagree | 84 (10.8) | |
|
|
nPEP will promote HIV drug resistance |
|
||
|
|
|
Agree | 212 (27.3) | |
|
|
|
Neutral | 308 (39.6) | |
|
|
|
Disagree | 257 (33.1) | |
|
|
nPEP will promote HIV risky behavior |
|
||
|
|
|
Agree | 256 (32.9) | |
|
|
|
Neutral | 302 (38.9) | |
|
|
|
Disagree | 219 (28.2) | |
|
|
Feasible to provide nPEP in place |
|
||
|
|
|
Agree | 712 (91.6) | |
|
|
|
Neutral | 57 (7.3) | |
|
|
|
Disagree | 8 (1.0) | |
|
|
Worry about being blamed for prescribing nPEP due to no nPEP drug indication | 583 (75.0) | ||
|
|
Necessary to have expert consensus for nPEP | 693 (89.2) | ||
|
|
Necessary to establish outpatient for nPEP | 620 (79.8) | ||
|
|
Concerns about prescribing nPEP |
|
||
|
|
|
Increased risk behavior | 291 (37.5) | |
|
|
|
Poor medication adherence | 310 (39.9) | |
|
|
|
HIV drug resistance | 238 (30.6) | |
|
|
|
Side effects | 438 (56.4) | |
|
|
|
High cost | 452 (58.2) | |
|
|
|
No specific guidance for nPEP | 159 (20.5) | |
|
|
|
No nPEP drug indication | 126 (16.2) | |
|
|
|
Resources reduced for HIV-positive patients | 121 (15.6) | |
|
|
|
Other problems | 40 (5.1) | |
anPEP: nonoccupational postexposure prophylaxis.
boPEP: occupational postexposure prophylaxis.